Skip to main content
SpringerLink
Log in

Tacrolimus and Mycophenolate Mofetil Regimens in Transplantation

Benefits and Pitfalls

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Immunosuppression, although necessary to enable the graft to escape the consequences of immune surveillance, carries some risks for the patient. There is an associated increase in neoplasms, opportunistic infections and end-organ toxicity In addition, even with excellent patient compliance, rejection (acute and chronic) remains a major limitation that contributes to the loss or decrease in the function of the allograft. New drugs have been added to the armamentarium of immunosuppressive agents to suppress allograft rejection and to rescue grafts from cyclosporin-resistant rejection. With the availability of these immunosuppressive agents, it has become increasingly difficult to choose the appropriate combination of immunosuppressants with a beneficial effect for the patient and for the allograft. We describe 2 new immunosuppressive agents and some of their different uses in solid organ transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Starzl TE, Todo S, Fung J, et al. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989; II: 1000–4

    Article  Google Scholar 

  2. Allison AC, Almquist SJ, Muller CD, et al. In vitro immunosuppressive effects of mycophenolic acid and ester pro-drug, RS-61443. Transplant Proc 1991; 23: 10–4

    PubMed  CAS  Google Scholar 

  3. Sollinger HW, Deierhoi MH, Beizer FO, et al. RS-61443 a phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428–32

    Article  PubMed  CAS  Google Scholar 

  4. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987; 40: 1256–65

    Article  PubMed  CAS  Google Scholar 

  5. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of Cyclopsorin A and FK506. Clin Immunol Immunopathol 1996; 80: S40–5

    Article  PubMed  CAS  Google Scholar 

  6. Sawada S, Suzuki GEN, Kawase Y, et al. Novel immunosuppressive agent, FK506: in vitro effects on cloned T cell activation. J Immunol 1987; 139: 1797–803

    PubMed  CAS  Google Scholar 

  7. Ciancio G, Roth D, Burke G, et al. Renal transplantation in a new immunosuppressive era. Transplant Proc 1995; 27: 812–3

    PubMed  CAS  Google Scholar 

  8. Ciancio G, Rosen A, Loreto-Grand B, et al. The current advantage of FK506 in cadaver kidney transplantation. Transplant Proc 1996; 28: 1000–1

    PubMed  CAS  Google Scholar 

  9. Wagner K, Herget S, Heemann U. Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. Clin Nephrol 1996; 45: 332–5

    PubMed  Google Scholar 

  10. Shapiro R, Jordan ML, Scantlebury VP, et al. Tacrolimus in renal transplantation. Transplant Proc 1996; 28: 2117–8

    PubMed  CAS  Google Scholar 

  11. Tzakis A, Webb M, Nery J, et al. Experience with intestinal transplantation at the University of Miami. Transplant Proc 1996; 28: 2748–9

    PubMed  CAS  Google Scholar 

  12. Burke GW, Alejandro R, Ciancio G, et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. Transplant Proc 1995; 27: 3123–4

    PubMed  CAS  Google Scholar 

  13. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovas Surg 1996; 111: 764–72

    Article  CAS  Google Scholar 

  14. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60: 580–4

    Article  PubMed  CAS  Google Scholar 

  15. Przepiorka D, Ippoliti I, Woo M, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383–9

    PubMed  CAS  Google Scholar 

  16. Woodle ES, Thistlethwaite R, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation 1996; 62: 594–9

    Article  PubMed  CAS  Google Scholar 

  17. Vicenti F, Laskow DA, Neylan JF, et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U. S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 1576–81

    Article  Google Scholar 

  18. Pirsh JD. Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977–83

    Article  Google Scholar 

  19. Roth D, Colona J, Burke G, et al. Primary therapy with FK506 (FK) in kidney transplantation. Proceedings of the American Society of Transplant Physicians [abstract]. 15th Annual Meeting of the American Society of Transplant Physicians 1996 May; Chicago (IL); 264: 150

    Google Scholar 

  20. Sollinger HW, Knechtle SJ, Reed A, et al. Experience with 100 consecutive simultaneous kidney-pancreas transplants with bladder drainage. Ann Surg 1991; 214: 703–11

    Article  PubMed  CAS  Google Scholar 

  21. Hariharan S, Munda R, Cavallo T, et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation 1996; 61: 1161–5

    Article  PubMed  CAS  Google Scholar 

  22. Stratta RJ, Taylor RJ, Castaldo P, et al. FK506 induction and rescue therapy in pancreas transplant recipients. Transplant Proc 1996; 28: 991–2

    PubMed  CAS  Google Scholar 

  23. Alloway RR, Russell WC, Gaber LW, et al. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. Transplant Proc 1996; 28: 995–7

    PubMed  CAS  Google Scholar 

  24. Gruessner RWG, Burke G, Stratta R, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61: 261–73

    Article  PubMed  CAS  Google Scholar 

  25. Xenos ES, Ciancio G, Burke GW, et al. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. Clin Transpl 1997; 11: 497–9

    CAS  Google Scholar 

  26. Ciancio G, Burke G, Roth D, et al. Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. Transplantation 1997; 63: 785–8

    Article  PubMed  CAS  Google Scholar 

  27. Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transpl 1997; 11: 243–9

    CAS  Google Scholar 

  28. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 23: 1767–9

    Article  Google Scholar 

  29. Groth CG, Ohlman S, Gannedahl G, et al. New immunosuppressive drugs in transplantation. Transplant Proc 1993; 25: 2681–3

    PubMed  CAS  Google Scholar 

  30. Deierhoi MH, Kauffman RS, Hudson SL, et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single centre. Ann Surg 1993; 217: 476–84

    Article  PubMed  CAS  Google Scholar 

  31. Sollinger HW, Beizer FO, Deierhoi MH, et al. RS-61443 (Mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 1992; 216: 513–9

    Article  PubMed  CAS  Google Scholar 

  32. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029–37

    Article  Google Scholar 

  33. Solliger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225–32

    Article  Google Scholar 

  34. Klupp J, Bechstein WO, Platz KP, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation: First results. Transplant Int 1997; 10: 223–8

    Article  CAS  Google Scholar 

  35. Klintmalm GB, Asher NL, Busuttil RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993; 25: 697

    PubMed  CAS  Google Scholar 

  36. Gavlik, Golberg MG, Tsarouchan A, et al. Mycophenolate mofetil rescue therapy in liver transplant recipients. Transplant Proc 1997; 29: 549–52

    Article  PubMed  CAS  Google Scholar 

  37. Freise CE, Herbet M, Osorio RW, et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc 1993; 25: 1758–9

    PubMed  CAS  Google Scholar 

  38. McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transpl 1996; 10: 140–5

    CAS  Google Scholar 

  39. Garcia-Morales R, Carreno M, Mathew J, et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-Flow assays in kidney transplant recipients. J Clin Invest 1997; 99: 1118–29

    Article  PubMed  CAS  Google Scholar 

  40. Roth D, Colona J, Burke GW, et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 1998; 65: 248–52

    Article  PubMed  CAS  Google Scholar 

  41. Mendez R, for the FK506 MMF Dose-Ranging Kidney Transplant Study Group. FK506 and mycophenolate mofetil in renal transplant recipients: six-months results of a multicenter, randomized dose ranging trial. Transplant Proc 1998; 30: 1287–9

    Article  PubMed  CAS  Google Scholar 

  42. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of Tacrolimus/Prednisone versus Tacrolimus/ Prednisone/Mycophenolate Mofetil in cadaveric renal transplantation-first report [abstract # 293]. Program and Abstracts of the 16th Annual Scientific Meeting of the American Society of Transplant Physicians; 1997 May; Chicago (IL)

  43. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant recipients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 1997; 5: 225–32

    Article  CAS  Google Scholar 

  44. Weppler D, Khan R, Fragulidis GP, et al. Status of liver and gastrointestinal transplantation at the University of Miami. In: JM Cecka, PI Terasaki, editors. Clinical Transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory; 1996; 14: 187–201

    Google Scholar 

  45. Karatzas T, Khan F, Tzakis AG. Clinical intestinal transplantation: experience in Miami. Transplant Proc 1997; 29: 1787–9

    Article  PubMed  CAS  Google Scholar 

  46. Regazzi MB, Alessiani M, Reggiani P, et al. Pharmacokinetics of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. Transplant Proc 1997; 29: 1857–60

    Article  PubMed  CAS  Google Scholar 

  47. Iacona I, Alessiani M, Spada M, et al. Mycophenolic acid in combination with FK506: a pharmacokinetic study in piglets after small-bowel transplantation. Transplant Proc 1997; 29: 701–2

    Article  PubMed  CAS  Google Scholar 

  48. Alessiani M, Spada M, Costa A, et al. Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression. Transplant Proc 1997; 29: 691–2

    Article  PubMed  CAS  Google Scholar 

  49. Tzakis AG, Nery JR, Thompson A, et al. New immunosuppression regimens in clinical intestinal transplantation. Transplant Proc 1997; 29: 683–5

    Article  PubMed  CAS  Google Scholar 

  50. Stratta RJ. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multicenter report: the FK/MMF Multi-Centre Study Group. Transplant Proc 1997; 29: 654–5

    Article  PubMed  CAS  Google Scholar 

  51. Burke GW, Ciancio G, Garcia-Morales R, et al. Evidence for microchimerism in peripheral blood, bone marrow and skin following donor bone marrow/kidney-pancreas transplantation at 3 years. Transplant Proc 1998; 30: 1555

    Article  PubMed  CAS  Google Scholar 

  52. Burke GW, Ricordi C, Karatzas T, et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: Evidence for augmentation of chimerism. Transplant Proc 1997; 29: 1207–8

    Article  PubMed  CAS  Google Scholar 

  53. Burke GW, Ciancio G, Alejandro R, et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. Transplant Proc 1998; 30: 1544–5

    Article  PubMed  CAS  Google Scholar 

  54. Ciancio G, Burke G, Levi D, et al. Simultaneous pancreas/kidney transplantation without antibody therapy induction. J Urol 1998; 709A: 159

    Google Scholar 

  55. Ciancio G, Burke G, Viciana A, et al. Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. Transplant Proc 1998; 30: 1536–7

    Article  PubMed  CAS  Google Scholar 

  56. Garcia-Morales R, Esquenazi V, Zucker K, et al. Assessment of the effects of cadaveric donor bone marrow on chimerism kidney transplant recipients by the polymerase chain reaction-flow technique. Transplant Proc 1997; 29: 1219–21

    Article  PubMed  CAS  Google Scholar 

  57. Garcia-Morales R, Esquenazi V, Carreno M, et al. PCR-flow analysis used to detect the levels of chimerism in peripheral blood of bone-marrow infused organ allograft recipients at the time of rejection episodes. Transplant Proc 1997; 29: 2179–80

    Article  PubMed  CAS  Google Scholar 

  58. Ciancio G, Carreno M, Mathew J, et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK506 and OKT3 induction therapy. Transplant Proc 1996; 28: 943–4

    PubMed  CAS  Google Scholar 

  59. Garcia-Morales R, Carreno M, Mathew J, et al. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation 1998; 65: 956–65

    Article  PubMed  CAS  Google Scholar 

  60. Ciancio G, Garcia-Morales R, Burke GW, et al. Donor bone marrow, chimerism, histocompatibility and renal allograft rejection. Transplant Proc 1999; 31: 679

    Article  PubMed  CAS  Google Scholar 

  61. Garcia-Morales R, Esquenazi V, Zucker K, et al. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation 1996; 62: 1149–60

    Article  PubMed  CAS  Google Scholar 

  62. Tanabe K, Koga S, Takahashi K, et al. Diabetes mellitus after renal transplantation under FK506 (tacrolimus) as primary immunosuppression. Transplant Proc 1996; 28: 1304–5

    PubMed  CAS  Google Scholar 

  63. Herget S, Heemann U, Friedrich J, et al. Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection. Clin Nephrol 1996; 45: 352–4

    PubMed  Google Scholar 

  64. Eberkard O, Kliem V, Oldhafer K, et al. How best to use tacrolimus (FK506) for treatment of steroid and OKT3-resistant rejection after renal transplantation. Transplantation 1996; 61: 1345–9

    Article  Google Scholar 

  65. Jordan ML, Shapiro R, Naraghi R, et al. Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc 1196; 28: 2119–20

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Transplantation, University of Miami School of Medicine, P.O. Box 012440, Miami, FL, 33101, USA

    Gaetano Ciancio, George W. Burke, David Roth & Joshua Miller

Authors
  1. Gaetano Ciancio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George W. Burke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joshua Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ciancio, G., Burke, G.W., Roth, D. et al. Tacrolimus and Mycophenolate Mofetil Regimens in Transplantation. BioDrugs 11, 395–407 (1999). https://doi.org/10.2165/00063030-199911060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911060-00004

Keywords

Search

Navigation